These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4732567)

  • 21. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease in morphine's analgesic action and increase in its cataleptic action by 6-hydroxydopamine injected bilaterally into caudate and putamen areas; partial restoration by L-DOPA plus decarboxylase inhibition.
    Nakamura K; Kuntzman R; Maggio A; Conney AH
    Neuropharmacology; 1973 Dec; 12(12):1153-60. PubMed ID: 4798737
    [No Abstract]   [Full Text] [Related]  

  • 23. L-Dopa and imipramine: biochemical and behavioral interaction.
    Friedman E; Gershon S
    Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevention of the haloperidol-induced blockade of a conditioned avoidance response by l-dopa.
    Ruiz M; Monti JM
    Eur J Pharmacol; 1972 Oct; 20(1):93-6. PubMed ID: 4637948
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of L-dopa on putrescine levels in the brain and the liver of the rat.
    Harik SI
    Eur J Pharmacol; 1979 Mar; 54(3):235-42. PubMed ID: 428424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the mechanism of L-dopa-induced postural hypotension in the cat.
    Dhasmana KM; Spilker BA
    Br J Pharmacol; 1973 Mar; 47(3):437-51. PubMed ID: 4147189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopa-induced locomotor stimulation after inhibition of extracerebral decarboxylase.
    Bartholini G; Blum JE; Pletscher A
    J Pharm Pharmacol; 1969 May; 21(5):297-301. PubMed ID: 4390121
    [No Abstract]   [Full Text] [Related]  

  • 28. Localization of the site of the central sympatho-inhibitory action of 1-Dopa in dogs and cats.
    Schmitt H; Fenard S
    Eur J Pharmacol; 1973 May; 22(2):212-6. PubMed ID: 4715222
    [No Abstract]   [Full Text] [Related]  

  • 29. Suppression by alpha-methyltyrosine of ethanol-induced locomotor stimulation: partial reversal by L-dopa.
    Engel J; Strömbom U; Svensson TH; Waldeck B
    Psychopharmacologia; 1974 Jul; 37(3):275-9. PubMed ID: 4153095
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
    Maj J; Pawlowski L; Sarnek J
    Adv Biochem Psychopharmacol; 1974; 10():253-6. PubMed ID: 4846541
    [No Abstract]   [Full Text] [Related]  

  • 31. Dopa reversal of hypoxia-induced disruption of the conditioned avoidance response.
    Brown R; David JN; Carlsson A
    J Pharm Pharmacol; 1973 May; 25(5):412-4. PubMed ID: 4146399
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of L-dopa alone and in combination with dopa decarboxylase inhibitors on the arterial pressure and heart rate of dogs.
    Minsker DH; Scriabine A; Stokes AL; Stone CA; Torchiana ML
    Experientia; 1971 May; 27(5):529-31. PubMed ID: 5132586
    [No Abstract]   [Full Text] [Related]  

  • 33. REM inhibitory effect of L-DOPA infusion during human sleep.
    Gillin JC; Post RM; Wyatt RJ; Goodwin FK; Snyder F; Bunney WE
    Electroencephalogr Clin Neurophysiol; 1973 Aug; 35(2):181-6. PubMed ID: 4124610
    [No Abstract]   [Full Text] [Related]  

  • 34. Metabolism of 5-fluoro-dopa and 6-fluoro-dopa enantiomers in aggregating cell cultures of fetal rat brain.
    Wiese C; Cogoli-Greuter M; Argentini M; Mäder T; Weinreich R; Winterhalter KH
    Biochem Pharmacol; 1992 Jul; 44(1):99-105. PubMed ID: 1632842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bizarre social behaviour in rats induced by a combination of a peripheral decarboxylase inhibitor and DOPA.
    Lammers AJ; van Rossum JM
    Eur J Pharmacol; 1968 Dec; 5(1):103-6. PubMed ID: 5718509
    [No Abstract]   [Full Text] [Related]  

  • 36. The formation of 3,4-dihydroxy-L-phenylalanine from L-meta-tyrosine by rat liver and beef adrenal medulla.
    Tong JH; D'Iorio A; Benoiton NL
    Biochem Biophys Res Commun; 1971 May; 43(4):819-26. PubMed ID: 4397921
    [No Abstract]   [Full Text] [Related]  

  • 37. The O-methylated derivative of L-DOPA, 3-O-methyl-L-DOPA, fails to inhibit neuronal and non-neuronal aromatic L-amino acid decarboxylase.
    Soares-da-Silva P; Parada A; Serrão P
    Brain Res; 2000 Apr; 863(1-2):293-7. PubMed ID: 10773222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional effects of L-dihydroxyphenylalanine (L-dopa) on norepinephrine metabolism in rat brain.
    Romero JA; Chalmers JP; Cottman K; Lytle LD; Wurtman RJ
    J Pharmacol Exp Ther; 1972 Feb; 180(2):277-85. PubMed ID: 5010674
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues.
    Sharpless NS; Tyce GM; Owen CA
    Life Sci I; 1973 Feb; 12(3):97-106. PubMed ID: 4696602
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypothalamic secretion of dopamine after inhibition of aromatic L-amino acid decarboxylase activity.
    Reymond MJ; Porter JC
    Endocrinology; 1982 Oct; 111(4):1051-6. PubMed ID: 6811255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.